Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomi... by Kato, Ken, Prof, Cho, Byoung Chul, Prof, Takahashi, Masanobu, MD, Okada, Morihito, Prof, Lin, Chen-Yuan, MD, Chin, Keisho, MD, Kadowaki, Shigenori, MD, Ahn, Myung-Ju, Prof, Hamamoto, Yasuo, Prof, Doki, Yuichiro, Prof, Yen, Chueh-Chuan, Prof, Kubota, Yutaro, MD, Kim, Sung-Bae, Prof, Hsu, Chih-Hung, Prof, Holtved, Eva, MD, Xynos, Ioannis, MD, Kodani, Mamoru, MSc, Kitagawa, Yuko, Prof

Get full text

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials by Drilon, Alexander, MD, Siena, Salvatore, Prof, Dziadziuszko, Rafal, MD, Barlesi, Fabrice, MD, Krebs, Matthew G, MD, Shaw, Alice T, Prof, de Braud, Filippo, Prof, Rolfo, Christian, MD, Ahn, Myung-Ju, MD, Wolf, Jürgen, Prof, Seto, Takashi, MD, Cho, Byoung Chul, Prof, Patel, Manish R, MD, Chiu, Chao-Hua, MD, John, Thomas, MD, Goto, Koichi, MD, Karapetis, Christos S, Prof, Arkenau, Hendrick-Tobias, MD, Kim, Sang-We, MD, Ohe, Yuichiro, MD, Li, Yu-Chung, MD, Chae, Young K, MD, Chung, Christine H, Prof, Otterson, Gregory A, Prof, Murakami, Haruyasu, MD, Lin, Chia-Chi, MD, Tan, Daniel S W, MD, Prenen, Hans, Prof, Riehl, Todd, PharmD, Chow-Maneval, Edna, PhD, Simmons, Brian, PharmD, Cui, Na, PhD, Johnson, Ann, MS, Eng, Susan, PharmD, Wilson, Timothy R, PhD, Doebele, Robert C, MD

Get full text

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study by Hui, Rina, Prof, Özgüroğlu, Mustafa, Prof, Villegas, Augusto, MD, Daniel, Davey, MD, Vicente, David, MD, Murakami, Shuji, MD, Yokoi, Takashi, MD, Chiappori, Alberto, MD, Lee, Ki Hyeong, MD, de Wit, Maike, Prof, Cho, Byoung Chul, Prof, Gray, Jhanelle E, MD, Rydén, Anna, PhD, Viviers, Louis, MD, Poole, Lynne, MSc, Zhang, Yiduo, PhD, Dennis, Phillip A, MD, Antonia, Scott J, MD

Get full text

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study by Gainor, Justin F, MD, Curigliano, Giuseppe, Prof, Kim, Dong-Wan, Prof, Lee, Dae Ho, Prof, Besse, Benjamin, Prof, Baik, Christina S, MD, Doebele, Robert C, MD, Cassier, Philippe A, MD, Lopes, Gilberto, MD, Tan, Daniel S W, MD, Garralda, Elena, MD, Paz-Ares, Luis G, Prof, Cho, Byoung Chul, Prof, Gadgeel, Shirish M, MD, Thomas, Michael, Prof, Liu, Stephen V, MD, Taylor, Matthew H, MD, Mansfield, Aaron S, MD, Zhu, Viola W, MD, Clifford, Corinne, MS, Zhang, Hui, PhD, Palmer, Michael, PhD, Green, Jennifer, BS, Turner, Christopher D, MD, Subbiah, Vivek, MD

Get full text

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim result... by Sequist, Lecia V, MD, Han, Ji-Youn, Prof, Ahn, Myung-Ju, Prof, Cho, Byoung Chul, MD, Yu, Helena, MD, Kim, Sang-We, Prof, Yang, James Chih-Hsin, Prof, Lee, Jong Seok, MD, Su, Wu-Chou, MD, Kowalski, Dariusz, MD, Orlov, Sergey, PhD, Cantarini, Mireille, MD, Verheijen, Remy B, PhD, Mellemgaard, Anders, MD, Ottesen, Lone, MD, Frewer, Paul, MSc, Ou, Xiaoling, PhD, Oxnard, Geoffrey, MD

Get full text

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study by Schuler, Martin, Prof, Cho, Byoung Chul, MD, Sayehli, Cyrus Michael, MD, Navarro, Alejandro, MD, Soo, Ross A, MBBS, Richly, Heike, MD, Cassier, Philippe Alexandre, MD, Tai, David, MBBS, Penel, Nicolas, MD, Nogova, Lucia, MD, Park, Se Hoon, MD, Schostak, Martin, MD, Gajate, Pablo, MD, Cathomas, Richard, MD, Rajagopalan, Prabhu, PhD, Grevel, Joachim, PhD, Bender, Sebastian, PhD, Boix, Oliver, PhD, Nogai, Hendrik, MD, Ocker, Matthias, MD, Ellinghaus, Peter, PhD, Joerger, Markus, MD

Get full text

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, pla... by Vansteenkiste, Johan F, Prof Dr, Cho, Byoung Chul, MD, Vanakesa, Tonu, MD, De Pas, Tommaso, MD, Zielinski, Marcin, Prof, Kim, Moon Soo, MD, Jassem, Jacek, Prof, Yoshimura, Masahiro, MD, Dahabreh, Jubrail, MD, Nakayama, Haruhiku, MD, Havel, Libor, MD, Kondo, Haruhiko, MD, Mitsudomi, Tetsuya, Prof, Zarogoulidis, Konstantinos, Prof, Gladkov, Oleg A, MD, Udud, Katalin, MD, Tada, Hirohito, MD, Hoffman, Hans, Prof, Bugge, Anders, MD, Taylor, Paul, MD, Gonzalez, Emilio Esteban, Prof, Liao, Mei Lin, Prof, He, Jianxing, MD, Pujol, Jean-Louis, Prof, Louahed, Jamila, PhD, Debois, Muriel, MSc, Brichard, Vincent, MD, Debruyne, Channa, MD, Therasse, Patrick, MD, Altorki, Nasser, MD

Get full text

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial by Ellis, Peter M, Dr, Shepherd, Frances A, Prof, Millward, Michael, Prof, Perrone, Francesco, PhD, Seymour, Lesley, Prof, Liu, Geoffrey, MD, Sun, Sophie, MD, Cho, Byoung Chul, MD, Morabito, Alessandro, MD, Leighl, Natasha B, MD, Stockler, Martin R, Prof, Lee, Christopher W, MD, Wierzbicki, Rafal, MD, Cohen, Victor, MD, Blais, Normand, MSc, Sangha, Randeep S, MD, Favaretto, Adolfo G, MD, Kang, Jin Hyoung, MD, Tsao, Ming-Sound, Prof, Wilson, Carolyn F, MSc, Goldberg, Zelanna, MD, Ding, Keyue, PhD, Goss, Glenwood D, Prof, Bradbury, Penelope Ann, MBBCh

Get full text

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial by Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

Get full text

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEY... by Machiels, Jean-Pascal, Prof, Tao, Yungan, MD, Licitra, Lisa, Prof, Burtness, Barbara, Prof, Tahara, Makoto, Prof, Rischin, Danny, Prof, Alves, Gustavo, MD, Lima, Iane Pinto Figueiredo, MD, Hughes, Brett G M, MBBS, Pointreau, Yoann, MD, Aksoy, Sercan, Prof, Laban, Simon, Prof, Greil, Richard, Prof, Burian, Martin, Prof, Hetnał, Marcin, MD, Delord, Jean-Pierre, Prof, Mesía, Ricard, MD, Taberna, Miren, MD, Waldron, John N, MD, Simon, Christian, Prof, Grégoire, Vincent, Prof, Harrington, Kevin J, Prof, Swaby, Ramona F, MD, Zhang, Yayan, PhD, Gumuscu, Burak, MD, Bidadi, Behzad, MD, Siu, Lillian L, Prof

Get full text

First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 by Soo, Ross A, Dr, Anderson, Benjamin O, Prof, Cho, Byoung Chul, MD, Yang, Chih-Hsin, Prof, Liao, Meilin, Prof, Lim, Wan-Teck, MB, Goldstraw, Peter, Prof, Mok, Tony S, Prof

Get full text